Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Wallis, Robert S ^a   Jakubiec, Wesley ^b   Mitton Fry, Mark ^a   Ladutko, Lynn ^b   Campbell, Sheldon ^b,c   Paige, Darcy ^a   Silvia, Annette ^a   Miller, Paul F ^a  

^a PFIZER INC   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CALCITRIOL; ISONIAZID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PYRAZINAMIDE; RIFAMPICIN; SUTEZOLID; 2 NITRO 6 (4 (TRIFLUOROMETHOXY)BENZYLOXY) 6,7 DIHYDRO 5H IMIDAZO(2,1 B)(1,3)OXAZINE; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; ADAMANTANE; DRUG DERIVATIVE; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PNU-100480; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTIVE VALUE; BLOOD; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; GROWTH, DEVELOPMENT AND AGING; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; REPRODUCIBILITY; TIME;

MYCOBACTERIUM TUBERCULOSIS;

ADAMANTANE; ANTITUBERCULAR AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ETHYLENEDIAMINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLIDINONES; PYRAZINAMIDE; QUINOLINES; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84855928950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030479     Document Type: Article

References (33)

1. Caminero JA, Sotgiu G, Zumla A, Migliori GB, (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621-629.
2. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, et al. (1999) Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43: 2600-2606.
3. Kim KS, Bayer AS, (1987) Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis. J Antimicrob Chemother 19: 475-485.
4. Tuomanen E, (1986) Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 8 (Suppl 3): S279-S291.
5. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, et al. (2009) Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 53: 1314-1319.
6. Andries K, Gevers T, Lounis N, (2010) Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 54: 4540-4544.
7. Janulionis E, Sofer C, Schwander S, Simmons D, Kreiswirth B, et al. (2005) Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity. Infect Immun 73: 2595-2601.
8. Wallis RS, Palaci M, Vinhas S, Hise AG, Ribeiro FC, et al. (2001) A whole blood bactericidal assay for tuberculosis. J Infect Dis 183: 1300-1303.
9. Cheon SH, Kampmann B, Hise AG, Phillips M, Song HY, et al. (2002) Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 9: 901-907.
10. Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, et al. (2003) Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 187: 270-278.
11. Janulionis E, Sofer C, Song HY, Wallis RS, (2004) Lack of activity of oral clofazimine against intracellular M. tuberculosis in whole blood culture. Antimicrob Agents Chemother 48: 3133-3135.
12. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, et al. (2011) Biomarker assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 55: 567-574.
13. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
14. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, et al. (2008) Early bactericidal activity and pharmacokinetics of the Diarylquinoline TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 52: 2831-2835.
15. Koul A, Vranckx L, Dendouga N, Balemans W, Van dW I, et al. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283: 25273-25280.
16. Dhillon J, Andries K, Phillips PP, Mitchison DA, (2010) Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) 90: 301-305.
17. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, et al. (2007) A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176: 208-213.
18. Haxaire-Theeuwes, (2011) Phase 2 open-label trial of TMC207 in an MDR-TB treatment regimen. Union World Conf Lung Health 42.
19. Mendez S, Traslavina R, Hinchman M, Huang L, Green P, et al. (2009) The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother 53: 5114-5121.
20. Scorpio A, Collins D, Whipple D, Cave D, Bates J, et al. (1997) Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 35: 106-110.
21. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK, (2009) Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 53: 3720-3725.
22. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, et al. (2006) Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 147: 476-485.
23. Reddy VM, Einck L, Andries K, Nacy CA, (2011) In vitro interactions between new antitubercular candidates SQ109 and TMC207. Antimicrob Agents Chemother 54: 2840-2846.
24. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, et al. (2011) Rapid evaluation of candidate regimens for XDR-TB including PNU-100480, TMC207 and PA-824 using whole blood culture. Intl Workshop Clin Pharm TB Drugs 4: 19.
25. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V, (2011) Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS ONE 6: e17556.
26. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, et al. (2011) PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 239-245.
27. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
28. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, et al. (2009) Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 180: 371-376.
29. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, et al. (2011) Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (epub ahead of print).
30. Manjunatha U, Boshoff HI, Barry CE, (2009) The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2: 215-218.
31. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
32. Hu Y, Coates AR, (2011) Mycobacterium tuberculosis acg Gene Is Required for Growth and Virulence In Vivo. PLoS ONE 6: e20958.
33. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN, (2004) Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48: 4315-4321.